Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Polyhydramnios and Oligohydramnios https://emedicine.medscape.com/article/975821-overview

Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Neratinib: A Case Series and Summary of The Literature https://pubmed.ncbi.nlm.nih.gov/34800263/

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients https://pubmed.ncbi.nlm.nih.gov/37163123/

The Comparative Efficacy and Risk of Harms of the Intravenous and Subcutaneous Formulations of Trastuzumab in Patients With HER2-Positive Breast Cancer: A Rapid Review https://pubmed.ncbi.nlm.nih.gov/31829250/

Overview of Antibody-Drug Conjugates Nonclinical and Clinical Toxicities and Related Contributing Factors https://pubmed.ncbi.nlm.nih.gov/40491603/

Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations https://pubmed.ncbi.nlm.nih.gov/37554126/

Oral Mucositis Associated With Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment https://pubmed.ncbi.nlm.nih.gov/40712557/

Incidence of Antibody-Drug Conjugate-Related Hepatotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39703774/

T-DM1-Induced Thrombocytopenia in Breast Cancer Patients: New Perspectives https://pubmed.ncbi.nlm.nih.gov/32570117/

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36454580/

Lung Toxicity Induced by Anti-HER2 Antibody-Drug Conjugates for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38295890/